------------------------------------------------------------
[link removed]


** What’s New on AVAC.org and PrEPWatch.org
------------------------------------------------------------
October 30, 2019

Dear Advocates,

In case you missed it, this round-up of AVAC’s latest resources will keep your finger on the pulse of HIV prevention advocacy!

Planning for Rollout: Report
A new publication, The Dapivirine Ring: Key Learnings from Like-Product Introductions ([link removed]) , from AVAC and the OPTIONS Consortium ([link removed]) looks at the rollout of other public health interventions and how they overcame barriers to acceptance. Some of the cases come from interventions that offered partial protection, others from products that are vaginally inserted. The dapivirine ring shares both of these characteristics, and this report offers specific lessons to guide early planning for rollout.

Demanding Access to Data: Report
Hot off the presses, Data Watch: Data Accessibility from Global Funders of HIV, TB and Malaria Programming ([link removed]) , published by amfAR ([link removed]) and supported by AVAC’s COMPASS program ([link removed]) , details which data are publicly available from each funder and which data are not. It focuses on the level of information available to grassroots advocates to monitor and understand how donor-funded programs for HIV, TB, and malaria are working in their own communities.

Designing Prevention That Works: Podcast
The latest episode of our Px Pulse podcast, Human-Centered Design and Prevention in the Real World ([link removed]) , explores an intensive human-centered design project, Breaking the Cycle of Transmission ([link removed]) , that is part of AVAC’s Prevention Market Manager program ([link removed]) and is trying to better understand and design programs that help adolescent girls and young women chart a journey to HIV prevention.

Adapting for Impact at Scale: Event recording
On October 22nd, the CSIS Global Health Policy Center ([link removed]) hosted a ([link removed]) n event ([link removed]) on recent developments in HIV prevention and treatment technology and how to bring those interventions to scale. Speakers included ViiV CEO Deborah Waterhouse ([link removed]) , PEPFAR leader Ambassador Deborah Birx ([link removed]) , Elizabeth Glaser Pediatric AIDS Foundation CEO Chip Lyons ([link removed]) , and AVAC’s Mitchell Warren
([link removed]) . Watch the video ([link removed]) to learn more about the successes and challenges in developing and delivering new products into existing service delivery, and how global programs, such as PEPFAR and the Global Fund, need to adapt. CSIS also launched a new report at the event: The Evolution and Future of HIV Prevention Technology: An HIV Policy Primer ([link removed]) .

Getting PrEP to Everyone Who Needs It, F/TAF and Women in Trials: Webinar
Check out the webinar AVAC hosted, Advocates’ Debrief on the Science of Daily F/TAF vs. TDF/FTC as PrEP ([link removed]) , for a review of the data and to explore questions about the safety profile of F/TAF. In early October, the FDA approved DESCOVY as PrEP for HIV-negative individuals (weighing 35kg or more), except for those who have receptive vaginal sex, which prompted outcry over Gilead’s failure to include women in clinical trials, among other questions related to F/TAF.

Keeping Up With the Pipeline of Prevention R&D: Infographic
Download the most recent update to our infographic that tracks the pipeline of non-vaccine HIV prevention products ([link removed]) , including oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals, implants and more. Also featured are the range of multipurpose prevention technologies in development, which aim to reduce the risk of HIV and STIs and/or provide effective contraception for women. And checkout the newest version of the Global PrEP Tracker ([link removed]) on PrEPWatch.org
([link removed]) that provides the latest data on programs, number of enrollments by country, regulatory status and more.

Best,
AVAC

============================================================
Forward This Issue Do you know someone who might be interested in receiving this newsletter?
** Forward > ([link removed])

Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
** Unsubscribe > ([link removed])

Contact Us T: +1 212 796 6423
E: ** [email protected] (mailto:[email protected])
W: ** www.avac.org ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])